AIMOVIG® (erenumab) overview [1]
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
Aimovig® is the first and only fully human a-CGRP receptor therapy designed to prevent migraine.1
Aimovig® is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.1 Aimovig has been shown to significantly reduce the frequency and severity of migraine.2,3
Learn more about how Aimovig can help your chronic migraine patients here [3].
References
- Aimovig SmPC, available at www.medicines.ie [4] [accessed June 2021]
- Tepper S, et al. Lancet Neurol 2017; 16: 425-434.
- Tepper SJ, et al. Neurology 2019; 92(20): e2309-e2320.